Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Недержание мочи

Список литературы

  1. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. - Feb 2004. - 93(3):324-3.
  2. Клинические рекомендации Российского общества урологов под редакцией Аляева, – М - 2017г.
  3. Harding, C., et al., EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms, 2023.
  4. Homma, Y., et al. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology, 2011. 77: 60.
  5. Brown, J.S., et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology, 2003. 61: 802.
  6. Shy, M., et al. Objective Evaluation of Overactive Bladder: Which Surveys Should I Use? Curr Bladder Dysfunct Rep, 2013. 8: 45.
  7. Arinzon, Z., et al. Clinical presentation of urinary tract infection (UTI) differs with aging in women. Arch Gerontol Geriatr, 2012. 55: 145.
  8. Ouslander, J.G., et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med, 1995. 122: 749.
  9. Goode, P.S., et al. Measurement of postvoid residual urine with portable transabdominal bladder ultrasound scanner and urethral catheterization. Int Urogynecol J Pelvic Floor Dysfunct, 2000. 11: 296.
  10. Simforoosh N, Dadkhah F, Hosseini SY, Asgari MA, Nasseri A, Safarinejad MR. Accuracy of residual urine measurement in men: comparison between real-time ultrasonography and catheterization. J Urol. 1997;158:59–61.
  11. Van Leijsen, S.A., et al. Can preoperative urodynamic investigation be omitted in women with stress urinary incontinence? A non-inferiority randomized controlled trial. Neurourol Urodyn, 2012. 31: 1118.
  12. Bodmer N. S. et al. Randomised Controlled Trials Assessing the Clinical Value of Urodynamic Studies: A Systematic Review and Meta-analysis //European urology open science. – 2022. – Т. 44. – С. 131-141.
  13. Clement K. D. et al. Urodynamic studies for management of urinary incontinence in children and adults //Cochrane database of systematic reviews. – 2013. – №. 10.
  14. Thiel, D.D., et al. Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? Urology, 2007. 69: 315. https://www.ncbi.nlm.nih.gov/pubmed/17320671.
  15. Al Afraa, T., et al. Normal lower urinary tract assessment in women: I. Uroflowmetry and post-void residual, pad tests, and bladder diaries. Int Urogynecol J, 2012. 23: 681.
  16. Scotti R. J. et al. Predictive value of urethroscopy as compared to urodynamics in the diagnosis of genuine stress incontinence //The Journal of reproductive medicine. – 1990. – Т. 35. – №. 8. – С. 772-776.
  17. Hadzi-Djokic, J., et al. Vesico-vaginal fistula: report of 220 cases. Int Urol Nephrol, 2009. 41: 299.
  18. Sarma, A.V., et al. Risk factors for urinary incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study. Urology, 2009. 73: 1203.
  19. Altman D. et al. Somatic comorbidity in women with overactive bladder syndrome //The Journal of urology. – 2016. – Т. 196. – №. 2. – С. 473-477.
  20. Brazzelli, M., et al. Absorbent products for containing urinary and/or fecal incontinence in adults. J Wound Ostomy Continence Nurs, 2002. 29: 45.
  21. Moore, K.N., et al. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. Urology, 2004. 63: 150.
  22. Fader, M., et al. Absorbent products for urinary/faecal incontinence: a comparative evaluation of key product designs. Health Technol Assess, 2008. 12: iii.
  23. Bryant, C.M., et al. Caffeine reduction education to im Bryant, C.M., et al. Caffeine reduction education to improve urinary symptoms. Br J Nurs, 2002. 11: 560. prove urinary symptoms. Br J Nurs, 2002. 11: 560.
  24. Hannestad, Y.S., et al. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG, 2003. 110: 247.
  25. Imamura, M., et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. Health Technol Assess, 2010. 14: 1.
  26. Glazener, C., et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet, 2011. 378: 328.
  27. Shamliyan, T.A., et al. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med, 2008. 148: 459.
  28. Rai, B.P., et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev, 2012. 12: CD003193.
  29. Reynolds, W.S., et al. Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis. Obstet Gynecol, 2015. 125: 1423.
  30. Maman, K., et al. Comparative efficacy and safety of medical  treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.Eur Urol, 2014. 65:7557 (https: // www.ncbi.nlm.nih.gov/pubmed/24275310)
  31. Buser, N., et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol, 2012. 62: 1040.
  32. Novara, G., et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol, 2008. 54: 740.
  33. Millard, R., et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol, 1999. 161: 1551.
  34. Chapple, C., et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int, 2014. 114: 418.
  35. DuBeau, C.E., et al. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn, 2012. 31: 1258.
  36. Sand, P.K., et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/=75 years) with overactive bladder syndrome. BJU Int, 2011. 107: 612.
  37. Wesnes, K.A., et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf, 2009. 8: 615.
  38. Herschorn, S., et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology.
  39. Chapple, C., et al. A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial. European Urology, 48 (2005), 464–470.
  40. Khullar, V., et al. Efficacy and Tolerability of Mirabegron, a b3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial. European Urology 63 (2013) 283 – 295.
  41. Резолюция Экспертного Совета по Уродинамике и Нейроурологии секции Нейроурологии Российского Общества Урологов (РОУ), Урология, 2022, № 6, 134-136.
  42. Cardozo L1, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008 Nov;102(9):1120-7. doi: 10.1111/j.1464-410X.2008.07939.x. Epub 2008 Oct 6.
  43. MacDiarmid, S., et al. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy. J Urol, 2016. 196: 809 (http:// www.ncbi.nlm.nih.gov/pubmed/27063854).
  44. Пушкарь, Ю.А. Куприянов, С.И. Гамидов, Г.Г. Кривобородов, Л.Г. Спивак, С.Х. Аль-Шукри и др. Оценка безопасности и эффективности лекарственного препарата Везустен у пациентов с гиперактивным мочевым пузырем. Урология, 2022. 3: 42-51.
  45. Green, A., et al. Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort Study. Drugs Aging. 2019 Mar;36(3):289-297. doi: 10.1007/s40266-018-00630-z. PMID: 30652263; PMCID: PMC6386184.
  46. Методическое руководство Минздрава РФ «Фармакотерапия у лиц пожилого и старческого возраста», 2018.
  47. Wagg, A., et al. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020 Feb;77(2):211-220. doi: 10.1016/j.eururo.2019.10.002. Epub 2019 Nov 13. PMID: 31733990.
  48. Blok, B., et al. EAU Guidelines on Neuro-Urology, 2023.
  49. Tannenbaum, C., et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging, 2012. 29: 639.https://pubmed.ncbi.nlm.nih.gov/22812538/.
  50. Boustani, M., et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health (2008)  4(3), 311–320. DOI:10.2217/1745509X.4.3.311.
  51. Li, J., et al. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. Int Urol Nephrol, 2013. 45: 679.
  52. Alan, C., et al. Efficacy of Duloxetine in the Early Management of Urinary Continence after Radical Prostatectomy. Curr Urol, 2015. 8: 43.
  53. Yumru, A.E., et al. The use of local 17beta-oestradiol treatment for improving vaginal symptoms associated with post-menopausal oestrogen deficiency. J Int Med Res, 2009. 37: 198.
  54. Cody, J.D., et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev, 2012. 10: CD001405.
  55. Гаджиева З.К. Функциональное состояние нижних мочевых путей и медикаментозная коррекция нарушений мочеиспускания у женщин в климактерическом периоде. Дис. …. канд. мед. наук, 2001, 189 с.
  56. Wang, C.J., et al. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol, 2011. 185: 219.
  57. Urinary incontinence in women: management [CG171]. 2013, National Institute for Health and Care Excellence.
  58. Vandersteen D. R., husmann D. A. Treatment of primary nocturnal enuresis persisting into adulthood //The Journal of urology. – 1999. – Т. 161. – №. 1. – С. 90-92.
  59. Khan, Z.A., et al. Long-term follow-up of a multicentre randomised controlled trial comparing tension-free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women. BJU Int, 2015. 115: 968.
  60. Kenton, K., et al. 5-year longitudinal followup after retropubic and transobturator mid urethral slings. J Urol, 2015. 193: 203.
  61. Ford, A.A., et al. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev, 2015: CD006375.
  62. Pushkar D, Kasyan G, Gvozdev M, Sosnowski R. Analysis of 1,000 cases of synthetic midurethral slings used for treatment of female urinary incontinence - a single-center experience. Cent European J Urol. 2011; 64(4):243-51.
  63. Пушкарь Д.Ю., Касян Г.Р. Отдаленные результаты использования свободной синтетической петли в лечении недержания мочи у женщин (восьмилетние результаты). Пушкарь Д.Ю., Касян Г.Р., // Урология. 2010. №2. С. 32.
  64. Novara, G., et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol, 2010. 58: 218.
  65. Barber, M.D., et al. Risk factors associated with failure 1 year after retropubic or transobturator midurethral slings. Am J Obstet Gynecol, 2008. 199: 666 e1.
  66. Zhao, Y., et al., Bulking agents - An analysis of 500 cases and review of the literature. Clin Exp Obstet Gynecol, 2016. 43: 666.
  67. Lapitan, M.C., et al. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev, 2016. 2: CD002912.
  68. Lee, K.S., et al. Outcomes following repeat mid urethral synthetic sling after failure of the initial sling procedure: rediscovery of the tension-free vaginal tape procedure. J Urol, 2007. 178: 1370.
  69. van der Ploeg, J.M., et al. Transvaginal prolapse repair with or without the addition of a midurethral sling in women with genital prolapse and stress urinary incontinence: a randomised trial. BJOG, 2015. 122: 1022.
  70. Borstad, E., et al. Surgical strategies for women with pelvic organ prolapse and urinary stress incontinence. Int Urogynecol J, 2010. 21: 179.
  71. Maher, C., et al. Laparoscopic colposuspension or tension-free vaginal tape for recurrent stress urinary incontinence and/or urethral sphincter deficiency-a randomised controlled trial. Neurourol Urodyn., 2004. 23: 433.
  72. Baessler K. et al. Surgery for women with pelvic organ prolapse with or without stress urinary incontinence //Cochrane Database of Systematic Reviews. – 2018. – №. 8.
  73. Maher, C., et al. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev, 2013: CD004014. https://www.ncbi.nlm.nih.gov/pubmed/23633316.
  74. Pushkar DY, Godunov BN, Gvozdev M, Kasyan GR. Complications of midurethral slings for treatment of stress urinary incontinence. Int J Gynaecol Obstet. 2011 Apr; 113 (1):54–7. doi: 10.1016/j. ijgo. 2010.10.024.
  75. Bauer, R.M., et al. Contemporary management of postprostatectomy incontinence. Eur Urol, 2011. 59: 985.
  76. Chung E. et al. Adjustable versus non‐adjustable male sling for post‐prostatectomy urinary incontinence: A prospective clinical trial comparing patient choice, clinical outcomes and satisfaction rate with a minimum follow up of 24 months //Neurourology an.
  77. Imamoglu M. A. et al. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence //European urology. – 2005. – Т. 47. – №. 2. – С. 209-213.
  78. Bauer, R.M., et al. Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int, 2011. 108: 94.
  79. Mangera, A., et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol, 2011. 60: 784.
  80. Mehta, S., et al. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil, 2013. 94: 1473.
  81. Chapple, C., et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol.
  82. Cohen, A.J., et al. Comparative Outcomes and Perioperative Complications of Robotic Vs Open Cystoplasty and Complex Reconstructions. Urology, 2016. 97: 172.
  83. Weil E. H. J. et al. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial //European urology. – 2000. – Т. 37. – №. 2. – С. 161-171.
  84. Schmidt R. A. et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence //The Journal of urology. – 1999. – Т. 162. – №. 2. – С. 352-357.
  85. van Kerrebroeck, P.E., et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol, 2007. 178: 2029.
  86. Heydari F., Motaghed Z., Abbaszadeh F. Could urinary tract infection cause female stress urinary incontinence? A clinical study //Nephro-Urology Monthly. – 2016. – Т. 8. – №. 1.
  87. Bai A. D. et al. Presence of urinary symptoms in bacteremic urinary tract infection: a retrospective cohort study of Escherichia coli bacteremia //BMC Infectious Diseases. – 2020. – Т. 20. – №. 1. – С. 1-10.
  88. Artibani W., Cerruto M. A. The role of imaging in urinary incontinence //BJU international. – 2005. – Т. 95. – №. 5. – С. 699-703.
  89. Hall S. A. et al. Associations of commonly used medications with urinary incontinence in a community based sample //The Journal of urology. – 2012. – Т. 188. – №. 1. – С. 183-189.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*